Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

Conditions:   HIV Infection;   Coronary Heart Disease
Interventions:   Drug: Pravastatin;   Drug: Rosuvastatin
Sponsor:   Donald Lloyd-Jones
Not yet recruiting - verified July 2016

Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years

Condition:   Chest Pain in Extremely Critical Condition
Intervention:  
Sponsor:   Qilu Hospital
Recruiting - verified July 2016

Portal Flow Pulsatility as a Risk Factor for Acute Kidney Injury After Cardiac Surgery

Conditions:   C.Surgical Procedure; Cardiac;   Acute Kidney Injury;   Postoperative Complications;   Right-Sided Heart Failure;   Cardio-Renal Syndrome
Intervention:   Procedure: Cardiac surgery
Sponsors:   Montreal Heart Institute;   The Montreal Health Innovations Coordinating Center (MHICC)
Not yet recruiting - verified July 2016

Documentation of Heart Failure in a Gulf Registry

Condition:   Heart Failure
Intervention:  
Sponsor:   Gulf Heart Association
Not yet recruiting - verified July 2016

Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Active, not recruiting - verified July 2016

The National Myelodysplastic Syndromes (MDS) Study

Condition:   Myelodysplastic Syndromes (MDS)
Intervention:   Other: Therapeutic
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Recruiting - verified June 2016

Transfusion-Associated Circulatory Overload Best Eliminated With Lasix

Condition:   Transfusion-associated Circulatory Overload
Interventions:   Drug: Furosemide;   Drug: Normal Saline
Sponsors:   Sunnybrook Health Sciences Centre;   University Health Network, Toronto;   Canadian Blood Services
Recruiting - verified July 2016

Liberal Oxygenation Versus Conservative Oxygenation in ARDS

Conditions:   Acute Respiratory Distress Syndrome;   Intensive Care
Intervention:   Drug: Modulation of Inspired Fraction of Oxygen (FiO2)
Sponsor:   Centre Hospitalier Universitaire de Besancon
Recruiting - verified July 2016

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified July 2016

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Conditions:   Coronary Artery Disease;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aspirin 100 mg;   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified May 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified July 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified May 2016

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified July 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Active, not recruiting - verified July 2016

Validation of Simple Acute Coronary Syndrome (SACS) Score

Conditions:   Chest Pain;   Acute Coronary Syndrome;   Angina;   Myocardial Infarction
Intervention:  
Sponsors:   Bayfront Health St Petersburg;   Bayfront Health Dade City;   Community Health Systems (CHS)
Enrolling by invitation - verified July 2016

CCC Project- Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsors:   Beijing Institute of Heart, Lung and Blood Vessel Diseases;   American Heart Association;   Chinese Society of Cardiology
Recruiting - verified July 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified July 2016

ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial

Condition:   Acute Respiratory Distress Syndrome
Interventions:   Drug: Aspirin 75mg;   Drug: Lactose powder
Sponsors:   Belfast Health and Social Care Trust;   Queen's University, Belfast;   Northern Ireland Clinical Trials Unit
Enrolling by invitation - verified July 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2016

Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome

Conditions:   Non ST Elevation Myocardial Infarction;   Unstable Angina
Intervention:   Procedure: Invasive management
Sponsors:   NHS National Waiting Times Centre Board;   University of Glasgow
Completed - verified July 2016

Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes

Conditions:   Non-ST Elevation Myocardial Infarction.;   Type 1 Myocardial Infarction.
Intervention:   Device: Fractional flow reserve
Sponsors:   NHS National Waiting Times Centre Board;   British Heart Foundation;   St. Jude Medical;   University of Glasgow
Active, not recruiting - verified July 2016

Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)

Condition:   Acute Coronary Syndrome
Intervention:   Drug: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Sponsor:   Samsung Medical Center
Recruiting - verified July 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified July 2016

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Pancytopenia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2016

The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction

Conditions:   Chest Pain;   Myocardial Infarction;   Acute Coronary Syndrome;   Coronary Artery Disease;   Myocardial Ischemia
Interventions:   Other: Cardiovascular Magnetic Resonance Imaging;   Other: Computed Tomography Angiography
Sponsors:   Maastricht University Medical Center;   Dutch Heart Foundation
Active, not recruiting - verified July 2016

Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study

Conditions:   Acute Myocardial Infarction;   Heart Attack;   Acute Coronary Syndrome;   Unstable Angina
Intervention:  
Sponsors:   Yale University;   Ohio State University
Completed - verified July 2016

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure

Conditions:   Acute Lung Injury;   Acute Respiratory Distress Syndrome;   Respiratory Failure
Interventions:   Drug: IV Ganciclovir;   Drug: Placebo
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   Genentech, Inc.
Active, not recruiting - verified July 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

The Clinical Evaluation of the Dose of Erythropoietins Trial

Condition:   Kidney Failure, Chronic
Interventions:   Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.;   Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.
Sponsor:   Giovanni FM Strippoli, MD
Completed - verified July 2016

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Conditions:   Dyslipidemia;   Atherosclerosis;   Acute Coronary Syndrome;   Cardiovascular Disease
Intervention:   Drug: RVX000222 (common name RVX-208)
Sponsor:   Resverlogix Corp
Completed - verified July 2016

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2016

Non-invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography

Conditions:   Stable Angina Pectoris;   Unstable Angina Pectoris;   Acute Myocardial Infarction
Intervention:   Procedure: Doppler echocardiography
Sponsor:   Norwegian University of Science and Technology
Completed - verified July 2016

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Hematologic Neoplasm;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Device: Isolex 300i plus MoAbs
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 2016